Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBUILD-2: Galcanezumab in Adolescents with Chronic Migraine
jRCT2031200254Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in chronic migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine headache days. Started Dec 2020; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2031200254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200254.